Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

55.94 -0.22 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,376,558
Open 56.95
Bid (Size) 54.00 (5)
Ask (Size) 58.52 (1)
Prev. Close 56.16
Today's Range 53.88 - 57.76
52wk Range 25.98 - 110.25
Shares Outstanding 95,640,600
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024. 
Via Benzinga
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-33.50%
-33.50%
1 Month
-0.92%
-0.92%
3 Month
+7.70%
+7.70%
6 Month
-17.24%
-17.24%
1 Year
+65.16%
+65.16%

More News

Read More
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
Via Investor's Business Daily
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
Peering Into Cytokinetics's Recent Short Interest
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
(CYTK) - Analyzing Cytokinetics's Short Interest
Via Benzinga
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stocks Mixed Amid Flood Of Economic Data
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
Why Cytokinetics (CYTK) Shares Are Falling
Via Benzinga
Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
Via Investor's Business Daily
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: April 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.